Dr. Feng's research interest is focused on the identification/discovery, optimization, and development of small molecule drug candidates for treating various cancers. The small molecules include but not limited to kinase inhibitors, inhibitors for epigenetic targets, and GPCR modulators, etc. He uses a combined approach of traditional medicinal chemistry methods, structure-based drug design, fragment-based drug design, and cheminformatics in pre-clinical drug discovery research.